

**LEMTRADA treatment can increase the risk of:**

**Autoimmune conditions such as:**

- a bleeding problem called immune thrombocytopenia (ITP)
- other blood disorders (including neutropenia, hemolytic anemia, and pancytopenia)
- disorders of the thyroid gland (hypo/hyperthyroidism)
- kidney disorders (nephropathies, including anti-glomerular basement membrane [anti-GBM] disease)
- liver disorders (autoimmune hepatitis)

Reference ID: 4512344

Infusion reactions (may occur more than 24 hours after the infusions), such as:

- hypersensitivity reactions (including anaphylaxis)
- fever
- hives
- irregular heartbeat
- nausea
- chest pain
- low blood pressure

Strokes and tears in the arteries that provide blood to the brain. Symptoms of stroke or tears in the arteries include:

- drooping of parts of your face
- weakness on one side
- sudden severe headache
- difficulty with speech
- neck pain

Malignancies such as:

- thyroid cancer
- melanoma
- lymphoproliferative disorders and lymphoma

VV-REG-0833078 0.1

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup><sub>iv</sub>